small molecule

DORYX

DOXYCYCLINE HYCLATE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyMAYNE PHARMA INTERNATIONAL PTY LTD

Drug detail

Brand nameDORYX
Active ingredientDOXYCYCLINE HYCLATE
StrengthEQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
8715724February 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DORYX patent cliff — loss of exclusivity February 2028 | CliffBio